Avian ultraviolet vision and frequency-dependent seed preferences.

It is well established that ultraviolet sensitivity plays an important role in the visually guided behaviour of birds. From a foraging perspective, evidence now exists that ultraviolet wavelengths are used by birds when foraging for insects, berries, seeds and mammals. Here, we present the results of two laboratory experiments that test the effect of removing (i) ultraviolet wavelengths and (ii) wavebands in the human-visible region on the frequency-dependent seed preferences of zebra finches (Taeniopygia guttata). Although the seeds and backgrounds used in our experiments reflected mainly at long wavelengths, we found that removal of ultraviolet wavelengths significantly changed the strength and direction of frequency dependence compared with full-spectrum illumination. We also found that the removal of ultraviolet wavelengths (300-400 nm) did not affect the strength of frequency dependence compared with the removal of short wavelengths (approximately 400-500 nm), medium wavelengths (approximately 500-600 nm) or long wavelengths (approximately 600-700 nm). Since frequency-dependent selection has direct consequences for the stability of prey populations and the spectral quality of ambient light is known to vary considerably with climate, time of day and local habitat geometry, our results suggest that ultraviolet wavelengths might play an important role in the dynamics of plant populations. However, we urge caution about overestimating the importance of ultraviolet wavelengths compared with wavelengths in the human-visible spectrum.

The use of autologous growth factors in periodontal surgical therapy: platelet gel biotechnology--case reports.

The role of polypeptide growth factors in periodontal regeneration has been documented through animal and human studies. Human platelets contain platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta) in their alpha granules. PDGF has been shown to play a role in periodontal regeneration. It has been demonstrated that TGF-beta has a very potent effect on cells associated with bone. The case reports presented demonstrate a new biotechnology in which platelet gel is used in combination with demineralized freeze-dried bone allografts for the treatment of periodontal osseous defects. The treated teeth presented with severe bone loss and a guarded prognosis. Platelet gel biotechnology was used as a novel treatment modality. A significant reduction in probing depths was noted, and radiographically significant amounts of new bone were visible as early as 2 months postoperative. Results up to 2 years postoperative are presented.

Systemic effects of an intraosseous injection of 2% lidocaine with 1:100,000 epinephrine.

The effect of a mandibular intraosseous injection of 2% lidocaine with 1:100,000 epinephrine on the heart rate and blood pressure of 20 volunteer patients was examined. Changes in blood pressure from preoperative levels were minimal and did not vary significantly at any time of measurement. The only statistically significant change in heart rate occurred immediately after the intraosseous injection (an increase of 12 beats per minute). In young healthy adults, the intraosseous injection of 1.5 mL of 2% lidocaine with 1:100,000 epinephrine resulted in a slight transient elevation in heart rate but had no significant effect on systolic or diastolic blood pressure.

Disease-based assessment of peripheral vascular disease in nursing facility patients.

OBJECTIVE: To determine the frequency of diagnosis of peripheral vascular disease (PVD) and selected related conditions in patients in a nursing facility, to determine the frequency of patients with risk factor(s) for or clinical evidence of PVD but without a diagnosis of PVD or a related condition, and to determine the frequency with which patients with and without a diagnosis of PVD or a related condition were treated with drug and nondrug therapies. DESIGN: A multicenter, disease-based, retrospective evaluation. SETTING: 41 nursing facilities in 6 regions of the US. PATIENTS: 4038 patients in a nursing facility: 827 patients with a PVD or related diagnosis; 2719 patients without a PVD or related diagnosis but with risk factor(s) for or clinical evidence of PVD; and 492 patients without a PVD or related diagnosis, risk factor(s), and clinical evidence. MAIN OUTCOME MEASURES: Evidence of disease and drug therapy for PVD. RESULTS: PVD was documented in 21% of patients; another 67% had risk factor(s) for or clinical evidence of PVD but no diagnosis of PVD or a related condition. Pentoxifylline was prescribed for 3% of the total sample and 12% of patients with PVD or a related condition. CONCLUSIONS: PVD appears to be inadequately evaluated in patients in a nursing facility. Disease treatment strategies should be developed and implemented to educate healthcare professionals and the general public about the need to acknowledge, assess, and treat PVD and related conditions.

Cost analysis of a home intravenous antibiotic program.

A cost analysis of a home intravenous antibiotic program was performed, and the feasibility of the program was evaluated. All fiscal data related to the antibiotic therapy of the 10 study patients were collected from the patients' billing records and charts. Inpatient charges for antibiotics, supplies, laboratory tests, and the hospital room were identified from the patient's bill. Personnel costs were obtained from a log maintained by the home antibiotic team members. Charges accrued were converted to costs using the cost-to-charge ratio for each cost center. Fiscal analysis was performed using a subgroup of six patients with osteomyelitis. For all the patients, the mean duration of home therapy was 26 days. Inpatient treatment averaged 15.9 days. No major catheter-related problems were identified. For the osteomyelitis patients, the total cost of therapy, both inpatient and outpatient, was $57,854. If all of the therapy for this subgroup of patients had been provided on an inpatient basis, the total cost would have been $98,314. The home intravenous antibiotic program was determined to be feasible and cost-effective.